Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
Luca Arcaini,Côme Bommier,Juan Pablo Alderuccio,Michele Merli,Nicole Fabbri,Maria Elena Nizzoli,Matthew J Maurer,Vittoria Tarantino,Simone Ferrero,Sara Rattotti,Annalisa Talami,Roberta Murru,Arushi Khurana,Raphael Mwangi,Marina Deodato,Emanuele Cencini,Francesca Re,Carlo Visco,Andrew L Feldman,Brian K Link,Marcia Torresan Delamain,Michele Spina,Ombretta Annibali,Alessandro Pulsoni,Andrés J M Ferreri,Caterina Cecilia Stelitano,Elsa Pennese,Thomas M Habermann,Luigi Marcheselli,Sunwoo Han,Isildinha M Reis,Marco Paulli,Izidore S Lossos,James R Cerhan,Stefano Luminari
DOI: https://doi.org/10.1016/j.eclinm.2024.102592
IF: 15.1
2024-04-11
EClinicalMedicine
Abstract:Background: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. Methods: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment. The model was externally validated in a pooled analysis of two independent cohorts from the University of Iowa and Mayo Clinic Molecular Epidemiology Resource and the University of Miami. Findings: We identified 501 eligible patients. After multivariable modeling, lactate dehydrogenase (LDH) above upper normal limit, hemoglobin <12 g/dL, absolute lymphocyte count <1 × 109/L, platelets <100 × 109/L, and MZL subtype (nodal or disseminated) were independently associated with inferior PFS. The proposed MZL International Prognostic index (MZL-IPI) combined these 5 factors, and we defined low (LRG, 0 factors, 27%), intermediate (IRG, 1-2 factors, 57%) and high (HRG, 3+ factors, 16%) risk groups with 5-y PFS of 85%, 66%, and 37%, respectively (c-Harrell = 0.64). Compared to the LRG, the IRG (Hazard Ratio [HR] = 2.30, 95% CI 1.39-3.80) and HRG (HR = 5.41, 95% CI 3.12-9.38) had inferior PFS. Applying the MZL-IPI to the pooled US cohort (N = 353), 94 (27%), 192 (54%), and 67 (19%) patients were classified as LRG, IRG, and HRG, respectively, and the model was validated for PFS (log-rank test p = 0.0018; c-Harrell = 0.578, 95% CI 0.54-0.62). The MZL-IPI was also prognostic for OS in both the training and the external validation sets. Interpretation: MZL-IPI is a new prognostic score for use in all patients with MZL considered for systemic treatment. Funding: The MER was supported by P50 CA97274 and U01 CA195568.